Targeting Mammalian Target of Rapamycin: Prospects for the Treatment of Inflammatory Bowel Diseases

Lashgari, Naser‐Aldin; Roudsari, Nazanin Momeni; Momtaz, Saeideh; Ghanaatian, Negar; Kohansal, Parichehr; Farzaei, Mohammad Hosein; Afshari, Khashayar; Sahebkar, Amirhossein; Abdolghaffari, Amir Hossein

doi:10.2174/0929867327666200504081503

Cited by 25 publications

(19 citation statements)

References 104 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…mTORC1 is activated by metabolic status and regulates lipid metabolism along with other basic cellular processes [ 92 , 93 , 94 ], whereas mTORC2 is sensitive to growth factors and controls cytoskeleton, cell metabolism and survival [ 95 , 96 ]. Activation of the mTOR pathway in IECs has been shown to induce inflammation [ 97 ]. Among phospholipids linked to mTORC signaling, phosphatidylinositol (3,4,5)-trisphosphate is involved in inflammation [ 98 ].…”

Section: Major Iecs’ Phospholipids Their Metabolism the Role In Ibd And Therapeutic Potentialmentioning

confidence: 99%

Fat of the Gut: Epithelial Phospholipids in Inflammatory Bowel Diseases

Boldyreva

Морозова

Saydakova³

et al. 2021

IJMS

View full text Add to dashboard Cite

Inflammatory bowel diseases (IBD) comprise a distinct set of clinical symptoms resulting from chronic inflammation within the gastrointestinal (GI) tract. Despite the significant progress in understanding the etiology and development of treatment strategies, IBD remain incurable for thousands of patients. Metabolic deregulation is indicative of IBD, including substantial shifts in lipid metabolism. Recent data showed that changes in some phospholipids are very common in IBD patients. For instance, phosphatidylcholine (PC)/phosphatidylethanolamine (PE) and lysophosphatidylcholine (LPC)/PC ratios are associated with the severity of the inflammatory process. Composition of phospholipids also changes upon IBD towards an increase in arachidonic acid and a decrease in linoleic and a-linolenic acid levels. Moreover, an increase in certain phospholipid metabolites, such as lysophosphatidylcholine, sphingosine-1-phosphate and ceramide, can result in enhanced intestinal inflammation, malignancy, apoptosis or necroptosis. Because some phospholipids are associated with pathogenesis of IBD, they may provide a basis for new strategies to treat IBD. Current attempts are aimed at controlling phospholipid and fatty acid levels through the diet or via pharmacological manipulation of lipid metabolism.

show abstract

Section: Major Iecs’ Phospholipids Their Metabolism the Role In Ibd And Therapeutic Potentialmentioning

confidence: 99%

Fat of the Gut: Epithelial Phospholipids in Inflammatory Bowel Diseases

Boldyreva

Морозова

Saydakova³

et al. 2021

IJMS

View full text Add to dashboard Cite

show abstract

“…Other pathways such as TGFβ/P13K/AKT/mTOR and TLR/P38MAPK/mTOR also upregulate inflammatory mediators. 33 In another way, the TLR4-MyD88-MAPK signaling pathway and the NF-κB pathway upregulate mTOR-dependent autophagy, hence inducing CVD. Thus, mTOR is critical for endothelial and cardiomyocyte development that modulate apoptotic, autophagy and oxidative pathways.…”

Section: Ppar Pathwaymentioning

confidence: 99%

Ginger: A complementary approach for management of cardiovascular diseases

et al. 2021

Self Cite

View full text Add to dashboard Cite

Cardiovascular disease (CVD) is a leading cause of morbidity and mortality worldwide. Inflammation and oxidative stress play critical roles in progression of various types of CVD. Broad pharmacological properties of ginger (the rhizome of Zingiber officinale) and its bioactive components have been reported, suggesting that they can be a therapeutic choice for clinical use. Consistent with its rich phenolic content, the anti-inflammatory and antioxidant properties of ginger have been confirmed in many studies. Ginger modifies many cellular processes and in particular was shown to have potent inhibitory effects against nuclear factor kappa B (NF-κB); signal transducer and activator of transcription; NOD-, LRR-, and pyrin domain-containing proteins; toll-like receptors; mitogenactivated protein kinase; and mammalian target of rapamycin signaling pathways. Ginger also blocks pro-inflammatory cytokines and the activation of the immune system. Ginger suppresses the activity of oxidative molecules such as

show abstract

“…The mammalian target of rapamycin (mTOR) is a member of serine kinase/threonine‐protein kinase phosphatidylinositol‐3 kinase (PIKK) family, and an essential regulator in inflammatory pathways. Activation of the mTOR pathway in the intestinal epithelial cells is effective in initiating inflammation and can lead to IBD 31 . Likewise, the mTOR/nuclear (NF)‐kB activation leads to overproduction of ‐γ, IL‐6, IL‐8, IL‐1, and TNF‐α, all of which lead to IBD.…”

Section: Pathology and Etiology Of Ibd: Inflammatory Processmentioning

confidence: 99%

Ginger and its constituents: Role in treatment of inflammatory bowel disease

et al. 2021

Self Cite

View full text Add to dashboard Cite

Inflammatory bowel diseases (IBD), with obscure etiology, are rising and are of worldwide concern. Of the various components of IBD pathogenesis and progression, irritation appears to play a major part. Investigations on the molecular and cellular pathways that activate the IBD provide the focus for the development of useful therapies. Ginger (the rhizome of Zingiber officinale) has a broad spectrum of clinical applications due to its anti‐inflammatory and anti‐oxidative functions. Inflammation and oxidative stress are the key pathogenic factors in many diseases, including IBD. The most established components of ginger are phenolic compounds called gingerols. A wide range of pharmacological activities of the potential therapeutic benefit of Z. officinale have been detailed. In this regard, the anti‐inflammatory activity of ginger has been documented by many researchers. It was shown that ginger is a potent inhibitor of the nuclear factor kappa B (NF‐κB), signal transducer of activators of transcription (STATs), Nod‐like receptor family proteins (NLRPs), toll‐like receptors (TLRs), mitogen‐activated protein kinase (MAPKs), and mTOR (mTOR) pathways, as well as inhibiting various pro‐inflammatory cytokines. In the present report, the potential application of ginger in the management of IBD is reviewed in detail, with an emphasis on the relevant properties of ginger and its bioactive components. The significance of the functions, side effects, and delivery of ginger to the digestive system for particular application in IBD are also considered.

show abstract

Targeting Mammalian Target of Rapamycin: Prospects for the Treatment of Inflammatory Bowel Diseases

Cited by 25 publications

References 104 publications

Fat of the Gut: Epithelial Phospholipids in Inflammatory Bowel Diseases

Fat of the Gut: Epithelial Phospholipids in Inflammatory Bowel Diseases

Ginger: A complementary approach for management of cardiovascular diseases

Ginger and its constituents: Role in treatment of inflammatory bowel disease

Contact Info

Product

Resources

About